key: cord-0945063-osoibhkv
authors: Uriel, Nir; Sayer, Gabriel; Clerkin, Kevin J.
title: Myocardial Injury in COVID-19 Patients: The Beginning or the End?
date: 2020-08-04
journal: J Am Coll Cardiol
DOI: 10.1016/j.jacc.2020.06.045
sha: d485eba67e4240795f8525596d83a1293011f14c
doc_id: 945063
cord_uid: osoibhkv

[Figure: see text]

The Beginning or the End?* Nir Uriel, MD, MSC, Gabriel Sayer, MD, Kevin J. Clerkin, MD, MSC T he past 6 months have been dominated by the highly contagious (R 0 of w3) (1) severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and the highly morbid and mortal coronavirus disease-2019 (COVID-19) pandemic that it has triggered. Early on, specific populations were identified to be at a greater risk for severe disease. Unsurprisingly, those with older age were among those at greater risk, though also prominent were individuals with cardiovascular disease (i.e., patients with coronary artery disease, heart failure, and atrial fibrillation) and even patients with cardiovascular risk factors (diabetes mellitus and hypertension). The pathophysiology associated with this increased risk may be linked to the role of the human angiotensinconverting enzyme 2 receptor as the portal of cell entry by SARS-CoV-2. However, whether the increased risk is because of the cardiovascular disease itself or medications used to treat it was initially unclear. 

The interplay of pre-existing cardiovascular disease (arrhythmia, heart failure, coronary artery disease) and severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) (pictured with spike protein binding to angiotensin-converting enzyme 2 receptor) on the heart.

ACE2 ¼ angiotensin-converting enzyme 2; TMPRSS2 ¼ transmembrane protease, serine 2.

Uriel et al. The main question that arises is whether COVID-19

is a disease that originates as a cardiovascular disease or whether cardiovascular involvement is a downstream consequence of severe COVID-19 ( Figure 1) 60% (>0.09 ng/ml) vs. 35% (0.03-0.09 ng/ml) vs. 15% (<0.03 ng/ml) (estimated from Figure 1 of Lala et al.)

CI ¼ confidence interval; COVID-19 ¼ coronavirus disease-2019; CVD ¼ cardiovascular disease; HR ¼ hazard ratio; hs-cTnI ¼ high-sensitivity cardiac troponin I; hs-cTnT ¼ high-sensitivity cardiac troponin T. Myocardial Injury in COVID-19 Patients 549

The reproductive number of COVID-19 is higher compared to SARS coronavirus

Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality

Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19

Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection

Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in

Covid-19 in critically ill patients in the Seattle region-case series

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy

KEY WORDS COVID-19, myocardial injury, myocarditis